Assessing Pathologic Response in Resected Lung Cancers: Current Standards, Proposal for a Novel Pathologic Response...

Area of Science:

• Oncology
• Pathology
• Clinical Trials

Background:

• Neoadjuvant treatment efficacy in non-small cell lung cancer (NSCLC) is assessed via pathologic evaluation of resected tissue.
• Major pathologic response (MPR) and pathologic complete response (pCR) are emerging surrogate endpoints in NSCLC clinical trials.
• Current methods for sampling and calculating MPR lack standardization, impacting study reliability.

Purpose of the Study:

• To develop a novel, standardized tool for assessing pathologic response in NSCLC after neoadjuvant therapy.
• To enhance methodological rigor in collecting and calculating MPR and pCR data.
• To facilitate the validation of MPR and pCR as reliable surrogate endpoints.

Main Methods:

• Development of a novel MPR calculator tool (MPRCT) for standardized data collection.
• MPRCT collects percentages of viable tumor, necrosis, and stroma, along with tumor dimensions.
• Proposed sampling strategies for different tumor sizes and response levels (pCR, MPR).

Main Results:

• The MPRCT enables standardized, comprehensive collection of pathologic response data.
• Calculations include unweighted and weighted MPR averages to account for slide proportions.
• The tool facilitates analysis to optimize sampling strategies balancing sensitivity and resource use.

Conclusions:

• The MPRCT provides a standardized methodology for pathologic assessment of neoadjuvant treatment in NSCLC.
• This standardization is crucial for validating MPR and pCR as surrogate endpoints.
• The tool addresses challenges in pathologic assessment and promotes systematic data collection.